{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:04:51Z","timestamp":1776834291178,"version":"3.51.2"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Oxford Biomedical research"},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2025,10,19]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant pleural effusion (MPE) is common, affecting approximately 15% of patients with cancer. Over recent years, there have been significant changes in both the diagnostic and therapeutic strategies for the condition, and recent epidemiological studies have shown improvements in survival across most major cancer types. However, it is currently unclear whether there has been an increase in survival in patients with MPE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records of patients diagnosed with MPE between 2015 and 2023 at Oxford University Hospitals were retrospectively reviewed. Patients were split into groups of equal size based on the date of MPE diagnosis and Kaplan-Meier survival analyses were performed. Subgroup analyses were conducted in patients with MPE by causative cancer type, performance status at diagnosis and treatment with systemic anti-cancer therapy. Cox regression analyses were carried out using the individual year of MPE diagnosis as an included variable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>742 patients with MPE were included. There was no improvement in survival length in patients managed in more recent years. This was consistent across effusions secondary to any primary malignancy; effusion secondary to lung cancer, mesothelioma or breast cancer; in patients with better performance status; and in patients who received systemic anti-cancer therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite recent changes in the management of MPE and improving survival trends in cancer overall, survival time following the development of MPE appears to have remained stagnant over the 8-year time period under study. This suggests that MPE should potentially be considered as a discrete clinical entity, necessitating investigation of oncological therapies specifically targeted to the pleural space.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjresp-2025-003609","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:50:22Z","timestamp":1764741022000},"page":"e003609","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Retrospective cohort study of survival length in malignant pleural effusion between 2015 and 2023"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5293-4786","authenticated-orcid":false,"given":"Craig","family":"Mounsey","sequence":"first","affiliation":[{"name":"Oxford Pleural Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"},{"name":"Department of Continuing Education, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-2282","authenticated-orcid":false,"given":"Nikolaos","family":"Kanellakis","sequence":"additional","affiliation":[{"name":"Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK"},{"name":"Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-6165","authenticated-orcid":false,"given":"Dinesh","family":"Addala","sequence":"additional","affiliation":[{"name":"Oxford Pleural Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"},{"name":"Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8501-8741","authenticated-orcid":false,"given":"Wui Mei","family":"Chew","sequence":"additional","affiliation":[{"name":"Oxford Pleural Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imogen","family":"Mechie","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beenish","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Oxford Pleural Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9965-0240","authenticated-orcid":false,"given":"Alguili","family":"Elsheikh","sequence":"additional","affiliation":[{"name":"Oxford Pleural Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"},{"name":"Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Sundaralingam","sequence":"additional","affiliation":[{"name":"Oxford Pleural Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Hallifax","sequence":"additional","affiliation":[{"name":"Oxford Pleural Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"},{"name":"Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najib","family":"Rahman","sequence":"additional","affiliation":[{"name":"Oxford Pleural Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"},{"name":"Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"2026010701520394000_12.1.e003609.1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0019-2016"},{"key":"2026010701520394000_12.1.e003609.2","doi-asserted-by":"crossref","DOI":"10.1515\/biol-2022-0575","article-title":"Malignant pleural effusion diagnosis and therapy","volume":"18","author":"Yang","year":"2023","journal-title":"Open Life Sci"},{"key":"2026010701520394000_12.1.e003609.3","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0145-2023","article-title":"Malignant pleural disease","volume":"19","author":"Piggott","year":"2023","journal-title":"Breathe (Sheff)"},{"key":"2026010701520394000_12.1.e003609.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076962","article-title":"25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis","volume":"384","author":"Shelton","year":"2024","journal-title":"BMJ"},{"key":"2026010701520394000_12.1.e003609.5","unstructured":"Bodtger U , Hallifax RJ . Epidemiology: why is pleural disease becoming more common? In: Pleural disease. European Respiratory Society, 2025: 1\u201312."},{"key":"2026010701520394000_12.1.e003609.6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00349-2018","article-title":"ERS\/EACTS statement on the management of malignant pleural effusions","volume":"52","author":"Bibby","year":"2018","journal-title":"Eur Respir J"},{"key":"2026010701520394000_12.1.e003609.7","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219698"},{"key":"2026010701520394000_12.1.e003609.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1415ST"},{"key":"2026010701520394000_12.1.e003609.9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12889-023-17571-x","article-title":"Trends in the incidence and survival of cancer in individuals aged 55 years and older in the United States, 1975-2019","volume":"24","author":"Cui","year":"2024","journal-title":"BMC Public Health"},{"key":"2026010701520394000_12.1.e003609.10","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-0423"},{"key":"2026010701520394000_12.1.e003609.11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215205","article-title":"Role of Immunotherapy in the Treatment of Cancer: A Systematic Review","volume":"14","author":"Ling","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026010701520394000_12.1.e003609.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306"},{"key":"2026010701520394000_12.1.e003609.13","unstructured":"Overview | lung cancer: diagnosis and management | guidance. NICE; 2019. Available: https:\/\/www.nice.org.uk\/guidance\/ng122"},{"key":"2026010701520394000_12.1.e003609.14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y"},{"key":"2026010701520394000_12.1.e003609.15","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205285"},{"key":"2026010701520394000_12.1.e003609.16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1470-2045(18)30294-8","article-title":"Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis","volume":"19","author":"Psallidas","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026010701520394000_12.1.e003609.17","unstructured":"R: the r project for statistical computing. 2025. Available: https:\/\/www.r-project.org"},{"key":"2026010701520394000_12.1.e003609.18","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.21037\/jtd-22-427","article-title":"Improving outcomes in malignant pleural mesothelioma in an integrated health care system","volume":"14","author":"Ossowski","year":"2022","journal-title":"J Thorac Dis"},{"key":"2026010701520394000_12.1.e003609.19","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.01019-2024","article-title":"External validation of the LENT and PROMISE prognostic scores for malignant pleural effusion","volume":"11","author":"Mounsey","year":"2025","journal-title":"ERJ Open Res"},{"key":"2026010701520394000_12.1.e003609.20","first-page":"100730","article-title":"Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer","volume":"36","author":"Carroll","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"2026010701520394000_12.1.e003609.21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043442","article-title":"Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative","volume":"11","author":"Snee","year":"2021","journal-title":"BMJ Open"},{"key":"2026010701520394000_12.1.e003609.22","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0341"},{"key":"2026010701520394000_12.1.e003609.23","unstructured":"Overview | Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | Guidance. NICE; 2018. Available: https:\/\/www.nice.org.uk\/guidance\/ta531"},{"key":"2026010701520394000_12.1.e003609.24","unstructured":"Overview | nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | guidance. NICE; 2022. Available: https:\/\/www.nice.org.uk\/guidance\/ta818"},{"key":"2026010701520394000_12.1.e003609.25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.658395","article-title":"Pleural Fluid Has Pro-Growth Biological Properties Which Enable Cancer Cell Proliferation","volume":"11","author":"Asciak","year":"2021","journal-title":"Front Oncol"},{"key":"2026010701520394000_12.1.e003609.26","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12874"},{"key":"2026010701520394000_12.1.e003609.27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12935-024-03211-w","article-title":"Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications","volume":"24","author":"Ge","year":"2024","journal-title":"Cancer Cell Int"},{"key":"2026010701520394000_12.1.e003609.28","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0590-4"},{"key":"2026010701520394000_12.1.e003609.29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fphys.2014.00221","article-title":"Tight junction physiology of pleural mesothelium","volume":"5","author":"Markov","year":"2014","journal-title":"Front Physiol"},{"key":"2026010701520394000_12.1.e003609.30","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bjc.1995.501","article-title":"Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study","volume":"72","author":"Goey","year":"1995","journal-title":"Br J Cancer"},{"key":"2026010701520394000_12.1.e003609.31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","article-title":"Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion","volume":"17","author":"Liu","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"2026010701520394000_12.1.e003609.32","doi-asserted-by":"crossref","first-page":"760683","DOI":"10.3389\/fimmu.2021.760683","article-title":"Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"2026010701520394000_12.1.e003609.33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12890-024-02886-1","article-title":"Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion","volume":"24","author":"Zeng","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2026010701520394000_12.1.e003609.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00471-X"},{"key":"2026010701520394000_12.1.e003609.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"2026010701520394000_12.1.e003609.36","unstructured":"New lung cancer screening roll out to detect cancer sooner. GOV.UK; 2023. Available: https:\/\/www.gov.uk\/government\/news\/new-lung-cancer-screening-roll-out-to-detect-cancer-sooner"},{"key":"2026010701520394000_12.1.e003609.37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/pp-2020-0147","article-title":"Survival and pleurodesis outcome in patients with malignant pleural effusion - a systematic review","volume":"6","author":"Hassan","year":"2021","journal-title":"Pleura Peritoneum"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2025-003609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:53:52Z","timestamp":1767779632000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2025-003609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,2]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjresp-2025-003609"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2025-003609","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}